Evangelos Dadiotis

Evangelos Dadiotis

Auto-generated profile, based on publicly available information

Evangelos Dadiotis

Northeastern University, Department of Pharmaceutical Sciences, Boston, Massachusetts 02115, U.S.A.

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
MGManos Gkikas
Manos Gkikas
EDEvangelos Dadiotis
Evangelos Dadiotis
MZMehreen Zaka
Mehreen Zaka
Nihal AlyNihal Aly
Nihal Aly
KCKim Chan
Kim Chan
Diomedes Elias LogothetisDiomedes Elias Logothetis
Diomedes Elias Logothetis
Ion channels are pore-forming transmembrane proteins that allow ions to move down an electrochemical gradient and across the channel pore and regulate many cell functions. Among them, are the G-protein–gated inwardly-rectifying K+ channels 1 (GIRK1) that are ubiquitously expressed with major functions in the brain and heart. Interestingly, significantly higher GIRK1 expression has been found in estrogen receptor positive (ER+) breast cancer patients compared to patients with HER2+ tumors or normal patients, and that was statistically correlated with shorter survival times and metastatic potential. Herein, we report the preparation of ∼4 nm GAT1508 -coated poly(ethylene glycol) gold nanoparticle (PEGylated AuNP) biomarker for ER+ breast cancer cell screening through an optical microscope. A urea-based small molecule, GAT1508, with an N-methylpyrazole benzyl group on one side and a bromo-thiophene tail on the other side, has been shown to predominantly bind GIRK1 subunits and specifically activate GIRK1/2 channels. Two derivatives of GAT1508were synthesized and characterized: an ethylamine derivative (GAT1508-EA) with a chain extension from the benzyl ring, and a propylamine derivative (GAT1508-PA) with a chain extension from the pyrazole ring. Electrophysiology (TEVC and whole-cell patch-clump) experiments as well as fluorescence studies (Thallium assay) showed that only GAT1508-PA inhibited GIRK1/2-mediated K+ currents in transfected HEK293 GIRK1 cells. Docking studies showed strong binding for the propylamine GAT1508 derivative, both in the amine form (GAT1508-PA) as well as in the amide form (GAT1508-PA-EG2; coupled with PEG as in the AuNPs). GAT1508 -PEG-AuNPs ( GAT1508 -NPs) were synthesized subsequently with ∼65 wt% metal loading. UV-Vis studies revealed the presence of the conjugated ligand at 260 nm. Flow cytometry studies showed binding of Alexa 594-labeled GAT1508 -NPs in ER+ MCF-7 breast cancer cells with a strong interaction, while incubation of fixed MCF-7 cells with a GAT1508 -NP solution led to optical detection of ER+ breast cancer cells, without the need of fluorescent dyes and additional amplification steps. Detection was not feasible in MDA-MB-231 cells, a triple (-) breast cell line that does not express GIRK1. This is the first study, to our knowledge, that couples nanotechnology with small molecule drug design and electrophysiology to develop ion channel-tracing molecular probes for the detection/screening of ER+ breast cancer.

8 October 2026 in Journal of Biological Chemistry
Verified
Journal Article
Open access
MGManos Gkikas
Manos Gkikas
EDEvangelos Dadiotis
Evangelos Dadiotis
MZMehreen Zaka
Mehreen Zaka
Nihal AlyNihal Aly
Nihal Aly
KCKim Chan
Kim Chan
Diomedes Elias LogothetisDiomedes Elias Logothetis
Diomedes Elias Logothetis
Ion channels are pore-forming transmembrane proteins that allow ions to move down an electrochemical gradient and across the channel pore and regulate many cell functions. Among them, are the G-protein-gated inwardly-rectifying K+ channels 1 (GIRK1) that are ubiquitously expressed with major functions in the brain and heart. Interestingly, significantly higher GIRK1 expression has been found in estrogen receptor positive (ER+) breast cancer patients compared to patients with HER2+ tumors or normal patients, and that was statistically correlated with shorter survival times and metastatic potential. Herein, we report the preparation of a ∼4 nm GAT1508-coated poly(ethylene glycol) gold nanoparticle (PEGylated AuNP) biomarker for ER+ breast cancer cell screening through an optical microscope. A urea-based small molecule, GAT1508, with an N-methylpyrazole benzyl group on its head and a bromo-thiophene on its tail, has been shown to predominantly bind GIRK1 subunits and specifically activate GIRK1/2 channels. Two derivatives of GAT1508 were synthesized and characterized: an ethylamine derivative (GAT1508-EA) with a chain extension from the benzyl ring, and a propylamine derivative (GAT1508-PA) with a chain extension from the pyrazole ring. Electrophysiology (TEVC and whole-cell patch-clump) experiments as well as fluorescence studies (Thallium assay) showed that only GAT1508-PA inhibited GIRK1/2-mediated K+ currents in transfected HEK293GIRK1 cells. Docking studies showed strong binding for the propylamine GAT1508 derivative, both in the amine form (GAT1508-PA) as well as in the amide form (GAT1508-PA-EG2; coupled with PEG as in the AuNPs). GAT1508-PEG-AuNPs (GAT1508-NPs) were synthesized subsequently with ∼65 wt% metal loading. UV-Vis studies revealed the presence of the conjugated ligand at 260 nm. Flow cytometry studies showed binding of Alexa 594-labeled GAT1508-NPs in ER+ MCF-7 breast cancer cells with a strong interaction, while incubation of fixed MCF-7 cells with a GAT1508-NP solution led to optical detection of ER+ breast cancer cells, without the need of fluorescent dyes and additional amplification steps. Detection was not feasible in MDA-MB-231 cells, a triple (-) breast cell line that does not express GIRK1. This, to our knowledge, is the first study that couples nanotechnology with small molecule drug design and electrophysiology to develop ion channel-tracing molecular probes for the detection/screening of ER+ breast cancer.

9 October 2026 in ACS Omega
Verified
Journal Article
Open access
EDEvangelos Dadiotis
Evangelos Dadiotis
RARomanos K. Antonopoulos
Romanos K. Antonopoulos
Antigoni CheilariAntigoni Cheilari
Antigoni Cheilari
AKAlexandra M. Kortsinoglou
Alexandra M. Kortsinoglou
EMEleni Melliou
Eleni Melliou
Prokopios MagiatisProkopios Magiatis
Prokopios Magiatis
The genus Psilocybe (Basidiomycota) comprises over 300 mushroom-forming species, many of which produce the secondary metabolite psilocybin, a prodrug of its dephosphorylated active metabolite psilocin. Psilocybin has recently attracted significant interest, with numerous active, recruiting, and completed clinical trials registered on ClinicalTrials.gov, primarily investigating its therapeutic potential in central nervous system disorders. Nonetheless, psilocybin remains a controlled substance in many jurisdictions, posing regulatory and legal challenges, not only for clinical research but also for forensic analysis, standardization, and quality control, since it is required as a reference material in chromatographic analyses. To this end, qNMR-based methods for rapid quantitation of psilocybin and psilocin were developed using wild-origin Psilocybe fruitbodies, preserved in the Dried Specimen Collection of the Mycetotheca ATHUM (NKUA). A dephosphorylation step was employed to convert psilocybin to psilocin, followed by GC-MS analysis, confirming its presence in mycelium of the isolated strains. Both native and dephosphorylated extracts were analyzed by 1H and 31P qNMR in D2O using calcium formate and dimethyl methylphosphonate as internal standards, respectively. To the best of our knowledge, this represents the first officially documented occurrence of a psychoactive Psilocybe species from Greece in the peer-reviewed scientific literature as well as the application of reference-standard-free qNMR methods for the quantitation of a psilocybin- and psilocin-containing fungus.